Novartis
Search results
Sandoz is a global leader in generic pharmaceuticals and biosimilars, with a mission to discover new ways to improve and extend people's lives. Learn more about our products, our quality standards, our innovation and sustainability efforts, and our partnerships and collaborations.
- About Sandoz
Sandoz is a division of Novartis that specializes in generic...
- People & Culture
People & Culture - Sandoz
- Careers
Join Sandoz, a global leader in generic and biosimilar...
- Board of Directors
Meet the board of directors of Sandoz, a global leader in...
- Sandoz 2023 Integrated Annual Report
This report provides a comprehensive overview of Sandoz,...
- 1 A Pharma GmbH
1 A Pharma GmbH is a supplier portal documentation page for...
- News
News - Sandoz
- Amoxi-Clav Tablet
> Sandoz is committed to antimicrobial stewardship Sandoz, a...
- About Sandoz
The company was founded in 1886 by Alfred Kern (1850–1893) and Edouard Sandoz (1853–1928) in Basel (Switzerland) under the name Chemiefirma Kern und Sandoz. Initially the company focused on production of dyes namely alizarin blue and auramine .
Sandoz is a division of Novartis that specializes in generic and biosimilar medicines. Learn more about its history, vision, and commitment to improving and extending people's lives around the world.
Aug 25, 2022 · Novartis announces the planned separation of Sandoz, its Generics and Biosimilars business, into an independent company by way of a 100% spin-off. Find out the latest news, timeline, and details of the spin-off process and the new Sandoz Group AG.
Oct 4, 2023 · Novartis has separated its Generics and Biosimilars business into an independent company, Sandoz, through a dividend-in-kind distribution to shareholders. Novartis reiterates its guidance for FY2023, with sales expected to grow high single digits and core operating income low double digits to mid-teens.
Sandoz is the leader in providing affordable medicines to patients worldwide. Learn about its mission, products, locations, employees, and updates on its LinkedIn page.
Aug 25, 2022 · Novartis announced its intention to separate Sandoz, its generics and biosimilars division, by way of a 100% spin-off in H2 2023. The spin-off aims to create the #1 European generics company and a global leader in biosimilars, and a more focused Novartis.
